Interleukin-23 serum level in systemic lupus erythematosus patients: Relation to disease activity and different disease parameters

Aim of the work: To assess serum level of interleukin 23 (IL-23) in systemic lupus erythematosus (SLE) patients and to evaluate its association with disease parameters and activity. Patients and methods: The study involved 40 SLE patients and 40 controls. The SLE disease activity index (SLEDAI) and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shimaa Rafat, Yomna Y. Mohamed, Mai E. Ahmed, Enas A. Abdelaleem
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Systemic lupus erythematosus Interleukin-23 Disease activity Damage Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/baf0f080954347b08fc427e516c646b6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:baf0f080954347b08fc427e516c646b6
record_format	dspace
spelling	oai:doaj.org-article:baf0f080954347b08fc427e516c646b62021-11-12T04:27:11ZInterleukin-23 serum level in systemic lupus erythematosus patients: Relation to disease activity and different disease parameters1110-116410.1016/j.ejr.2021.10.009https://doaj.org/article/baf0f080954347b08fc427e516c646b62022-04-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1110116421000971https://doaj.org/toc/1110-1164Aim of the work: To assess serum level of interleukin 23 (IL-23) in systemic lupus erythematosus (SLE) patients and to evaluate its association with disease parameters and activity. Patients and methods: The study involved 40 SLE patients and 40 controls. The SLE disease activity index (SLEDAI) and damage index (SDI) were assessed. Serum level of IL-23 was measured by enzyme linked immunosorbant assay (ELISA). Results: Patients were 38 females and 2 males (F:M 19:1),with a mean age of 31.3 ± 7.5 years (17–50 years) and disease duration 4.8 ± 2.9 years (1–13 years). Their mean SLEDAI was 14.3 ± 6.8 (3–32) and SDI 0.4 ± 0.5 (0–2). 85% of patients had photosensitivity, alopecia in 60%, malar rash in 57.5%, oral ulcers 52.5%, arthralgia/arthritis 47.5%, serositis and lupus nephritis in 27.5%, discoid rash in 22.5% and neuropsychiatric in 2.5%. Mean serum level of IL-23 was significantly elevated in patients (107.9 ± 17.3 ng/L; 72.7–165.5 ng/mL) compared to controls (91.6 ± 19.1 ng/L; 57.6–140.3 ng/mL; p < 0.001). IL-23 was significantly elevated in patients with oral ulcers (p = 0.03), arthritis (p < 0.001), lupus nephritis (p = 0.01), alopecia (p = 0.02) and positive anti-dsDNA (p < 0.001). IL-23 significantly correlated with SLEDAI (r = 0.89, p < 0.001), complement C3 (r = -0.55, p < 0.001) and C4 (r = -0.5, p = 0.001). IL-23 could significantly predict SLE at a cut-off 93.1 ng/L (sensitivity 80% and specificity 55%). Conclusion: IL-23 may be involved in the pathogenesis of SLE; especially in renal, mucocutaneous and musculoskeletal manifestations and it can be used as a disease activity biomarker. These findings support the possibility of its use as a therapeutic target in SLE.Shimaa RafatYomna Y. MohamedMai E. AhmedEnas A. AbdelaleemElsevierarticleSystemic lupus erythematosusInterleukin-23Disease activityDamageImmunologic diseases. AllergyRC581-607ENEgyptian Rheumatologist, Vol 44, Iss 2, Pp 139-143 (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	Systemic lupus erythematosus Interleukin-23 Disease activity Damage Immunologic diseases. Allergy RC581-607
spellingShingle	Systemic lupus erythematosus Interleukin-23 Disease activity Damage Immunologic diseases. Allergy RC581-607 Shimaa Rafat Yomna Y. Mohamed Mai E. Ahmed Enas A. Abdelaleem Interleukin-23 serum level in systemic lupus erythematosus patients: Relation to disease activity and different disease parameters
description	Aim of the work: To assess serum level of interleukin 23 (IL-23) in systemic lupus erythematosus (SLE) patients and to evaluate its association with disease parameters and activity. Patients and methods: The study involved 40 SLE patients and 40 controls. The SLE disease activity index (SLEDAI) and damage index (SDI) were assessed. Serum level of IL-23 was measured by enzyme linked immunosorbant assay (ELISA). Results: Patients were 38 females and 2 males (F:M 19:1),with a mean age of 31.3 ± 7.5 years (17–50 years) and disease duration 4.8 ± 2.9 years (1–13 years). Their mean SLEDAI was 14.3 ± 6.8 (3–32) and SDI 0.4 ± 0.5 (0–2). 85% of patients had photosensitivity, alopecia in 60%, malar rash in 57.5%, oral ulcers 52.5%, arthralgia/arthritis 47.5%, serositis and lupus nephritis in 27.5%, discoid rash in 22.5% and neuropsychiatric in 2.5%. Mean serum level of IL-23 was significantly elevated in patients (107.9 ± 17.3 ng/L; 72.7–165.5 ng/mL) compared to controls (91.6 ± 19.1 ng/L; 57.6–140.3 ng/mL; p < 0.001). IL-23 was significantly elevated in patients with oral ulcers (p = 0.03), arthritis (p < 0.001), lupus nephritis (p = 0.01), alopecia (p = 0.02) and positive anti-dsDNA (p < 0.001). IL-23 significantly correlated with SLEDAI (r = 0.89, p < 0.001), complement C3 (r = -0.55, p < 0.001) and C4 (r = -0.5, p = 0.001). IL-23 could significantly predict SLE at a cut-off 93.1 ng/L (sensitivity 80% and specificity 55%). Conclusion: IL-23 may be involved in the pathogenesis of SLE; especially in renal, mucocutaneous and musculoskeletal manifestations and it can be used as a disease activity biomarker. These findings support the possibility of its use as a therapeutic target in SLE.
format	article
author	Shimaa Rafat Yomna Y. Mohamed Mai E. Ahmed Enas A. Abdelaleem
author_facet	Shimaa Rafat Yomna Y. Mohamed Mai E. Ahmed Enas A. Abdelaleem
author_sort	Shimaa Rafat
title	Interleukin-23 serum level in systemic lupus erythematosus patients: Relation to disease activity and different disease parameters
title_short	Interleukin-23 serum level in systemic lupus erythematosus patients: Relation to disease activity and different disease parameters
title_full	Interleukin-23 serum level in systemic lupus erythematosus patients: Relation to disease activity and different disease parameters
title_fullStr	Interleukin-23 serum level in systemic lupus erythematosus patients: Relation to disease activity and different disease parameters
title_full_unstemmed	Interleukin-23 serum level in systemic lupus erythematosus patients: Relation to disease activity and different disease parameters
title_sort	interleukin-23 serum level in systemic lupus erythematosus patients: relation to disease activity and different disease parameters
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/baf0f080954347b08fc427e516c646b6
work_keys_str_mv	AT shimaarafat interleukin23serumlevelinsystemiclupuserythematosuspatientsrelationtodiseaseactivityanddifferentdiseaseparameters AT yomnaymohamed interleukin23serumlevelinsystemiclupuserythematosuspatientsrelationtodiseaseactivityanddifferentdiseaseparameters AT maieahmed interleukin23serumlevelinsystemiclupuserythematosuspatientsrelationtodiseaseactivityanddifferentdiseaseparameters AT enasaabdelaleem interleukin23serumlevelinsystemiclupuserythematosuspatientsrelationtodiseaseactivityanddifferentdiseaseparameters
_version_	1718431312604299264

Interleukin-23 serum level in systemic lupus erythematosus patients: Relation to disease activity and different disease parameters

Ejemplares similares